personalized medicine

Functional genomics firm The DNA Company acquired digital therapeutics app My Pain Sensei, giving it an AI development platform and a Health Canada medical device license.

Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.

The grants were awarded as part of Australia's Genomics Health Futures Mission, which was launched in 2018 as part of a broader health research initiative.

With its second offering in less than a year, the AI and analytics company will apply as much as $487,000 to repay debts. 

The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.

Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology. 

The health system said the donation will be used to advance its translational cancer research and build a dedicated Precision Health Center.